Nature Reviews Clinical Oncology

Papers
(The H4-Index of Nature Reviews Clinical Oncology is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Tasadenoturev active in DIPG1296
A new standard of care for advanced-stage urothelial carcinoma957
From little subclones grow mighty oaks917
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma894
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes871
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC743
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care730
Novel ICI–TKI combination improves HCC outcomes668
Ecological management of the microbiota in patients with cancer668
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC647
Hodgkin lymphoma: great progress with room for improvement572
Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines544
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime536
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials507
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety476
The emerging roles of circRNAs in cancer and oncology452
Current understanding and management of CAR T cell-associated toxicities417
Gut microbiota in colorectal cancer development and therapy401
Contrasting results with second-line CAR T cells in large B cell lymphoma395
Sacituzumab tirumotecan improves OS in mTNBC386
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials365
Ponatinib superior to imatinib in Ph+ ALL355
Mortality is similar with active monitoring354
From ESMO 2022353
Understanding and overcoming multidrug resistance in cancer330
Minimal residual disease as a target for liquid biopsy in patients with solid tumours319
Belzutifan as a new option in pheochromocytomas and paragangliomas268
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC267
Humanized mouse models for immuno-oncology research266
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence262
Harnessing cytokines and chemokines for cancer therapy261
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease259
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours252
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma252
Survival benefit with second-line combination in endometrial cancer250
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC249
Unresectable stage III non-small-cell lung cancer: state of the art and challenges246
Harnessing big data to characterize immune-related adverse events242
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer240
Craniospinal irradiation improves leptomeningeal metastasis control237
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs232
Spatial landscapes of cancers: insights and opportunities227
Improving outcomes in patients with oesophageal cancer215
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response210
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests203
Biomarkers for immunotherapy of hepatocellular carcinoma183
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship178
New CAPSTONE of SCLC therapy?177
Approvals in 2022: overall survival, dose optimization, new approvals and beyond177
SHINE a light: frontline ibrutinib for MCL173
Women with clinically node negative breast cancer can safely avoid axillary surgery165
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC165
From ESMO 2023: advances in lung cancer164
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC164
DREAMseq of therapy for BRAF-mutant melanoma157
Prospective comparisons support the use of navigational bronchoscopy148
Aumolertinib is effective in NSCLC145
Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma138
Targeting chromosomal instability in patients with cancer130
Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond127
Circulating tumour DNA — looking beyond the blood123
Domvanalimab plus zimberelimab shows promise in upper-tract cancers121
Long-term outcomes following CAR T cell therapy: what we know so far116
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer116
Mitigating acute chemotherapy-associated adverse events in patients with cancer114
Response to neoadjuvant endocrine therapy complements recurrence score112
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM110
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress106
From the ESMO Congress 2023105
Multiomics STEP up in correlative analysis of response to CAR T cells105
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas104
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC103
Newly approved cancer drugs in China — innovation and clinical benefit102
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL99
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma97
HAIC-FO improves outcomes in HCC95
Lung cancer in patients who have never smoked — an emerging disease94
Claudin 18.2 as a novel therapeutic target92
Enhancing immunotherapy with tumour-responsive nanomaterials86
Clinical implications of T cell exhaustion for cancer immunotherapy86
Combining CAR T cells effective in RRMM85
T-DXd effective as second-line therapy in G/GEJ cancers85
Targeted biopsy reduces detection of clinically insignificant cancer85
Second-line tarlatamab improves OS in SCLC83
0.23544216156006